Plain-English translation of NCT05429138 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Researchers want to understand whether anti-PD-1 immunotherapy or targeted therapies that are used to treat melanoma after surgery might affect fertility in young men and women. Right now, doctors don't have clear information about how these medications impact egg reserves in women or sperm quality in men, so this study will collect that information by testing fertility markers before, during, and after treatment.
Young adults with melanoma deserve to make informed decisions about their future fertility before starting cancer treatment. This study exists because there is very little human data on whether the medication affects reproductive health, leaving patients and doctors without clear answers to an important life question.
You likely qualify if…
You likely don't qualify if…
You will visit a fertility center three times: before your melanoma treatment starts, immediately after treatment ends (around one year later), and one year after your treatment is completely finished. At each visit, women will have blood tests to measure egg reserves and an ultrasound to count developing eggs, while men will provide a semen sample for analysis. You'll also answer a questionnaire about your health and lifestyle at each visit. The entire study spans about two years.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
France